Donald S. Middleton,M. D. Andrews,Paul A. Glossop,G. E. Gymer,David Hepworth,Alan S. Jessiman,Patrick S. Johnson,Malcolm MacKenny,Michael J. Pitcher,Tony Rooker,Alan Stobie,Kim Tang,Paul Morgan
A series of substituted benzylamines 2-48 were prepared as part of a strategy to identify structurally differentiated and synthetically more accessible selective serotonin reuptake inhibitors, relative to clinical candidate 1. In particular, 44 and 48; demonstrated low nanomolar potency and good selectivity, in a structurally simplified template and, in vivo, very low Vdu, significantly lower than l, and a more rapid T(max), consistent with our clinical objectives.